Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.

@article{Minnella2008IntravitrealB,
  title={Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.},
  author={Angelo Maria Minnella and Cristina M Savastano and Lucia Ziccardi and Andrea Scupola and Benedetto Falsini and Emilio Balestrazzi},
  journal={Acta ophthalmologica},
  year={2008},
  volume={86 6},
  pages={683-7}
}
PURPOSE To evaluate the efficacy and safety of intravitreal bevacizumab in proliferative diabetic retinopathy (PDR) patients. METHODS This interventional case series study included 15 eyes of 10 patients with bilateral PDR: 13 eyes with severe PDR and active new vessels (NV) and two eyes with recurrent vitreous haemorrhages. Study eyes received a single intravitreal injection of 1.25 mg (0.05 ml) bevacizumab. All eyes were followed up for 3 months, and eight of them for 9 months. Reinjection… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…